• Chimeric Therapeutics shares rose7.69%toAUD 0.056.• The company has a market capitalisation of approximatelyAUD 3.16 million.• The stock remains89.82% lower over the past year, highlighting the volatility associated with clinical-stage biotechnology companies.• Investors continue monitoring clinical progress across the company's cell therapy and oncology …
• Cynata Therapeutics shares rose7.69%toAUD 0.014.• The company has a market capitalisation of approximatelyAUD 3.41 million.• The stock remains90.67% lower over the past year, reflecting the volatility often associated with clinical-stage biotechnology companies.• Investors continue monitoring developments across the company's stem cell therapy programs …
• Vectus Biosystems shares rose9.38%toAUD 0.175.• The company has a market capitalisation of approximatelyAUD 10.8 million.• The stock has surged372.97% over the past year, making it one of the strongest-performing small-cap healthcare stocks.• Investors continue monitoring pipeline development, licensing opportunities and strategic partnerships.
• Ceryx Therapeutics shares rose8.33%toAUD 0.013.• The company has a market capitalisation of approximatelyAUD 17.78 million.• The stock remains97.83% lower over the past year, highlighting the volatility associated with early-stage biotechnology companies.• Investors continue monitoring pipeline developments, funding initiatives and future clinical milestones.
• ImexHS shares rose8.77%toAUD 0.31.• The company has a market capitalisation of approximatelyAUD 16.86 million.• The stock has gained19.23% over the past year, outperforming several small-cap technology peers.• Investors continue monitoring recurring revenue growth, software adoption and international expansion initiatives.
• Vectus Biosystems shares rose9.38%toAUD 0.175.• The company has a market capitalisation of approximatelyAUD 10.8 million.• The stock has surged372.97% over the past year, making it one of the strongest-performing small-cap healthcare stocks.• Investors continue monitoring pipeline development, licensing opportunities and strategic partnerships.
The flat quote reflects a company in transition: its headline gastrointestinal program did not deliver the clear efficacy result many investors had hoped for, and it is now repackaging its assets and opening a new front in metabolic health. The question in this article's …
On 13 July 2026, Tissue Repair (ASX:TRP) shares were unchanged at A$0.11, with no company announcement tied to that specific session. For a stock with a market value under A$7 million and modest turnover, price is usually driven by discrete catalysts — a clinical …
The unchanged price belies a significant strategic shift. Historically known for its "deoxymab" antibody platform and lead candidate PAT-DX1, Patrys repositioned in 2026: it acquired the private company Reliis and pivoted its near-term clinical focus toward central nervous system (CNS) therapeutics, with a delirium …
On 13 July 2026, CYV rose 12.5% to A$0.0135 over the snapshot period — a fraction of a cent, where on a stock priced at 1.35 cents a single tick can produce a large percentage swing. Its market capitalisation of about A$16.4 million sits …